atorvastatin has been researched along with Aberrant Crypt Foci in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Chang, WL; Clapper, ML; Cooper, HS | 1 |
Benya, R; Chiorean, M; Della'Zanna, G; Gostout, C; Heigh, R; Lawson, MJ; Levine, J; Limburg, PJ; Mahoney, MR; Mandrekar, SJ; Richmond, E; Rodriguez, L; Schoen, RE; Smyrk, TC; Sontag, SJ; Stoffel, E; Weinberg, DS; Ziegler, KL | 1 |
1 review(s) available for atorvastatin and Aberrant Crypt Foci
Article | Year |
---|---|
Dysplastic Aberrant Crypt Foci: Biomarkers of Early Colorectal Neoplasia and Response to Preventive Intervention.
Topics: Aberrant Crypt Foci; Adenoma; Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents; Aspirin; Atorvastatin; Carcinogenesis; Catechin; Clinical Trials as Topic; Colon; Colonoscopy; Colorectal Neoplasms; Dietary Supplements; Disease Models, Animal; Humans; Intestinal Mucosa; Lycopene; Mice; Mutation; Treatment Outcome | 2020 |
1 trial(s) available for atorvastatin and Aberrant Crypt Foci
Article | Year |
---|---|
Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.
Topics: Aberrant Crypt Foci; Aged; Antineoplastic Agents; Atorvastatin; Colorectal Neoplasms; Dietary Fiber; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Male; Middle Aged; Pyrroles; Sulindac; Survival Rate; Treatment Outcome | 2011 |